JAK Inhibitor Mechanism and Clinical Effects in Myeloproliferative Disorders

Introduction to JAK Inhibitors

• The American College of Hematology recommends JAK inhibitors as a treatment option for myeloproliferative neoplasms, which work by blocking constitutively activated JAK-STAT signaling that drives disease pathophysiology, but they inhibit both mutant and wild-type JAK2 equally, providing symptom control and reducing splenomegaly without eliminating the malignant clone 1, 2

Key Mechanistic Differences

• In myeloproliferative neoplasms, JAK2V617F and other driver mutations cause constitutive activation of the JAK2/STAT pathway independent of cytokine stimulation, which is fundamentally different from the cytokine-mediated JAK signaling targeted in autoimmune dermatologic conditions 1
• The JAK2V617F mutation is present in approximately 95% of polycythemia vera cases and 50-60% of essential thrombocythemia and primary myelofibrosis cases 3

Clinical Outcomes

• Ruxolitinib achieves spleen volume reduction ≥35% in approximately 60% of myelofibrosis patients and provides durable symptom control 1, 4
• In polycythemia vera, ruxolitinib achieves hematocrit control in 60% of hydroxyurea-resistant/intolerant patients and spleen volume reduction ≥35% in 38% 1, 2, 4
• Ruxolitinib improves overall survival in intermediate-2 or high-risk myelofibrosis compared to placebo and best available therapy 1, 2, 4

Disease Modification and Combination Strategies

• Only a minority of patients experience reduction in JAK2 allelic burden or improvement in bone marrow fibrosis with JAK inhibitor monotherapy 1, 2, 5
• Rational combinations with agents targeting downstream pathways are being explored to enhance disease-modifying activity 5, 6, 7, 8
• The combination of ruxolitinib with azacitidine produced an 82% response rate with 27% of patients showing improvement in bone marrow fibrosis grade 5, 6